| Literature DB >> 35668859 |
Stephen Amankwah1,2, Mekonen Adisu1,3, Kasahun Gorems4,5, Kedir Abdella1, Tesfaye Kassa1.
Abstract
Purpose: Despite the growing interest in bacteriophage (phage) usage for the prevention, control, and removal of bacterial biofilms, few scientific data exist on phage applications on medical implant surfaces, while none exists on multiple implants. In this study, we aimed to isolate, biophysically characterize and assess phages as potential antibiofilm agents to inhibit and remove multidrug-resistant (MDR) Pseudomonas aeruginosa biofilm on catheter and endotracheal tube surfaces.Entities:
Keywords: bacteriophage; biofilm; catheter; endotracheal tube; multidrug-resistant P. aeruginosa
Year: 2022 PMID: 35668859 PMCID: PMC9166914 DOI: 10.2147/IDR.S367460
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.177
Clinical Bacterial Isolates and Their Antimicrobial Resistance Patterns
| Isolates | Source | Antibiotic Resistance |
|---|---|---|
| Wound abscess | AMP, AMC, CTX, CXM, TZP, TET | |
| Sputum | AMP, AMC, AMK, CRO, CXM, CHL, SXT, CN, MEM | |
| Wound abscess | AMP, AMC, AMK, CXM, CHL, SXT, CRO, CTX, MEM | |
| Pleural fluid | AMP, AMC, CFZ, CXM, CHL, SXT, TET | |
| Wound abscess | AMP, AMC, CFZ, CAZ, CTX, CXM, CHL, SXT, | |
| Wound abscess | AMP, AMC, CAZ, CRO, CTX, CXM, CHL, SXT, CN, TET, TOB | |
| Urine | AMP, AMK, CRO, CXM, CIP, CN, NIT, NOR |
Abbreviations: PA, Pseudomonas aeruginosa, AMC, amoxicillin-clavulanic acid; AMK, amikacin; AMP, ampicillin; CAZ, ceftazidime; CFZ, cefazolin; CHL, chloramphenicol; CIP, ciprofloxacin; CN, gentamicin; CRO, ceftriaxone; CTX, cefotaxime; CXM, cefuroxime; MEM, meropenem; NIT, nitrofurantoin; NOR, norfloxacin; SXT, sulfamethoxazole-trimethoprim; TET, tetracycline; TOB, tobramycin; TZP, piperacillin-tazobactam.
Lytic Activity of Phages ΦJHS and ΦSMK Against Tested Bacterial Strains
| Bacterial Strain | Phage Sensitivity | |
|---|---|---|
| ΦJHS | ΦSMK | |
| + | + | |
| ++ | ++ | |
| ++ | ++ | |
| ++ | + | |
| + | + | |
| ++ | ++ | |
| ++ | ++ | |
| ++ | + | |
| – | – | |
| – | – | |
| – | – | |
| – | – | |
| – | – | |
| – | – | |
| – | – | |
| – | – | |
| – | – | |
Notes: (++), clear plaques or complete lysis; (+), turbid plaque or partial lysis; (–) no plaque or no lysis; (*), host.
Figure 1Medical implants used for biofilm experiment. (A) Foley balloon catheter. (B) Endotracheal tube. (C) 15-mm long catheter tube cut in half. (D) 12-mm long endotracheal tube cut in half. (E) Catheter segment and (F) endotracheal tube segment placed in (G) sterile 24-well culture plate.
Figure 2Plaques formed by bacteriophages (A) ΦJHS and (B) ΦSMK on the lawn of PA 1139 strain using the double agar overlay method. The bar corresponds to 1 mm.
Stability of Phages ΦJHS and ΦSMK to External Physical and Chemical Factors
| External Factors | Time and Conditions of Incubation | Percentage Viability of Phages ± SD | |
|---|---|---|---|
| ΦJHS | ΦSMK | ||
| 4°C* | 1 h | 100 ± 0.0 | 100 ± 0.0 |
| 15°C | 1 h | 100 ± 7.5 | 100 ± 4.4 |
| RT | 1 h | 100 ± 6.5 | 100 ± 3.2 |
| 37°C | 1 h | 100 ± 6.1 | 100 ± 6.5 |
| 40°C | 1 h | 100 ± 3.1 | 100 ± 5.5 |
| 50°C | 1 h | 76.9 ± 0.6 | 55.4 ± 2.5 |
| 90°C | 1 h | 0.0 ± 0.0 | 0.0 ± 0.0 |
| pH 2.0 | 1 h; 37°C | 0.0 ± 0.0 | 0.0 ± 0.0 |
| pH 4.0 | 1 h; 37°C | 38.0 ± 2.0 | 29.8 ± 0.6 |
| pH 7.0* | 1 h; 37°C | 100.0 ± 0.0 | 100.0 ± 0.0 |
| pH 10.0 | 1 h; 37°C | 78.9 ± 3.1 | 68.1 ± 1.1 |
| pH 12.0 | 1 h; 37°C | 0.0 ± 0.0 | 0.0 ± 0.0 |
| SM buffer* | 1.5 h; RT | 100 ± 0.0 | 100 ± 0.0 |
| Chloroform | 1.5 h; RT | 82.0 ± 2.5 | 70.8 ± 1.5 |
| Acetone | 1.5 h; RT | 0.0 ± 0.0 | 0.0 ± 0.0 |
| 96% ethanol | 1.5 h; RT | 0.0 ± 0.0 | 0.0 ± 0.0 |
| 48% ethanol | 1.5 h; RT | 90.0 ± 4.9 | 57.0 ± 2.1 |
Note: (*), controls.
Figure 3Biofilms formed by MDR PA clinical isolates cultured for 24 h at static non-renewal condition, as analyzed by crystal violet staining procedure and shown as O.D values measured at a wavelength of 630 nm. All assays were performed in triplicates. The values presented are mean ± SD from two readings of triplicate experiments (n = 6).
Figure 4Lytic activity of bacteriophages on biofilms formed by MDR PA clinical isolates after 6 h treatment with phages ΦJHS-PA1139 and ΦSMK-PA1139, as analyzed by crystal violet staining procedure and shown as O.D values measured at a wavelength of 630 nm. The values presented are mean ± SD from two readings of triplicate experiments (n= 6). Statistically significant differences between control and analyzed samples are marked with asterisks (p < 0.001 (⁎⁎⁎) in the multiple unpaired t-tests).
Figure 5Microbial load inhibition of MDR PA 1098 (A) and 1668 (B) biofilm formation on non-coated and phage-coated catheter and ET segments, quantified as log10CFU/mL. The values presented are mean ± SD from two counts of triplicate experiments (n= 6). Statistically significant differences between control and analyzed samples are marked with asterisks (p < 0.01 (⁎⁎), p < 0.001 (⁎⁎⁎) in the multiple unpaired t-tests).
Figure 6Microbial load reduction with 6 h phage treatment of MDR PA 1098 (A) and 1668 (B) biofilms formed on catheter and ET segments, quantified as log10CFU/mL. The values presented are mean ± SD from two counts of triplicate experiments (n = 6). Statistically significant differences between control and analyzed samples are marked with asterisks (p < 0.05 (⁎), p < 0.01 (⁎⁎), p < 0.001 (⁎⁎⁎) in the multiple unpaired t-tests).